HC Wainwright Lifts Earnings Estimates for Nuvectis Pharma

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – HC Wainwright lifted their Q3 2025 earnings per share estimates for Nuvectis Pharma in a note issued to investors on Tuesday, August 12th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.26) for the quarter, up from their prior estimate of ($0.28). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($1.52) EPS, FY2027 earnings at ($1.73) EPS and FY2028 earnings at ($2.03) EPS.

Nuvectis Pharma (NASDAQ:NVCT) last issued its earnings results on Tuesday, August 5th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.05).

Separately, Wall Street Zen cut Nuvectis Pharma from a “hold” rating to a “sell” rating in a report on Sunday, June 29th.

Nuvectis Pharma Stock Performance

Shares of NVCT opened at $6.43 on Thursday. Nuvectis Pharma has a 1 year low of $4.44 and a 1 year high of $11.80. The stock has a market cap of $163.71 million, a P/E ratio of -5.50 and a beta of -0.26. The stock’s 50-day moving average price is $7.65 and its two-hundred day moving average price is $8.24.

Insider Buying and Selling at Nuvectis Pharma

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri acquired 28,043 shares of the business’s stock in a transaction dated Wednesday, June 18th. The shares were acquired at an average price of $8.05 per share, for a total transaction of $225,746.15. Following the acquisition, the insider directly owned 2,976,203 shares of the company’s stock, valued at approximately $23,958,434.15. This trade represents a 0.95% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders bought 39,045 shares of company stock worth $314,300. Insiders own 30.52% of the company’s stock.

Hedge Funds Weigh In On Nuvectis Pharma

Several institutional investors have recently modified their holdings of NVCT. Marshall Wace LLP lifted its holdings in shares of Nuvectis Pharma by 191.0% during the 4th quarter. Marshall Wace LLP now owns 124,571 shares of the company’s stock valued at $674,000 after purchasing an additional 81,757 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Nuvectis Pharma by 68.7% during the 4th quarter. Northern Trust Corp now owns 25,725 shares of the company’s stock valued at $139,000 after purchasing an additional 10,472 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Nuvectis Pharma during the 4th quarter valued at about $34,000. Squarepoint Ops LLC bought a new position in shares of Nuvectis Pharma during the 4th quarter valued at about $103,000. Finally, Blue Zone Wealth Advisors LLC bought a new stake in Nuvectis Pharma in the 1st quarter valued at approximately $102,000. Institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.